NorthWest Biotherapeutics Inc (NWBO)

[ontologizer]

"help answer [my] question rather quickly" lol that's funny! TBH the first link is just too difficult to parse. I'm going to follow Charlie Munger's lead and throw that into the too difficult pile. Thank you for taking the time though!! I'm sure it's helpful to other's with a deeper understanding.

A couple things though:

Closed Testing Procedure - you are saying there is established precedence to split the alpha over the different endpoints?? Just confirming, because this doesn't seem to me how alpha works. I would think each endpoint has it's own distribution from which an alpha is calculated. Honestly, I don't know.

I thought I read that they considered going with alpha = .02 but ended up going with .05.


I am familiar with the fact that the endpoints where changed to use external controls from contemporaneous studies, I believe due to the number of crossovers(?) And am I correct in that the number of crossovers was one of the rationales as to why the study is assumed to be successful? The larger number of crossovers, this was an assumption or well-known?

I think those will be my final questions. Too steep a learning curve here. Wish you longs well, and that this treatment does in fact improve upon the current SOC.